

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**The United Laboratories International Holdings Limited**  
**聯邦制藥國際控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 3933)**

**PROPOSED ADOPTION OF  
THE 2023 SHARE AWARD SCHEME**

The Board proposes to adopt the 2023 Share Award Scheme in compliance with Chapter 17 of the Listing Rules.

The purposes of the 2023 Share Award Scheme are to:

- (i) recognise the contributions by certain selected participants with an opportunity to acquire a proprietary interest in the Company;
- (ii) encourage and retain such individuals for the continual operation and development of the Group;
- (iii) provide additional incentives for them to achieve performance goals;
- (iv) attract suitable personnel for the further development of the Group; and
- (v) motivate the selected participants to maximise the value of the Company for the benefits of both the selected participants and the Company,

with a view to achieving the objectives of increasing the value of the Group and aligning the interests of the selected participants with that of the Shareholders through ownership of the Shares.

The adoption of the 2023 Share Award Scheme is conditional upon the passing of the resolution by the Shareholders as set out in the notice of the extraordinary general meeting of the Company approving the 2023 Share Award Scheme and the Stock Exchange granting the approval for the listing of, and permission to deal in, the Shares which may fall to be issued and allotted pursuant to any awards that may be granted under the 2023 Share Award Scheme.

The extraordinary general meeting of the Company will be convened to consider and, if thought fit, approve, among others, the adoption of the 2023 Share Award Scheme. A circular of the Company containing, among others, (i) details relating to the adoption of the 2023 Share Award Scheme; (ii) the principal terms of the 2023 Share Award Scheme; and (iii) a notice convening the extraordinary general meeting is expected to be despatched to the Shareholders in due course.

## DEFINITIONS

*In this announcement, unless the context otherwise requires, the following expressions shall have the following meanings:*

“2023 Share Award Scheme”	the share award scheme for the eligible participants proposed to be conditionally adopted at the EGM
“Board”	the board of Directors
“Company”	The United Laboratories International Holdings Limited, a company incorporated in the Cayman Islands with limited liability and the issued Shares of which are listed on the Main Board of the Stock Exchange
“Director(s)”	the director(s) of the Company
“Group”	the Company and its subsidiaries
“Hong Kong”	the Hong Kong Special Administrative Region of the People’s Republic of China
“Listing Rules”	the Rules Governing the Listing of Securities on the Stock Exchange
“Share(s)”	the ordinary share(s) with par value of HK\$0.01 each in the share capital of the Company
“Shareholder(s)”	holder(s) of the Share(s)
“Stock Exchange”	The Stock Exchange of Hong Kong Limited

By Order of the Board  
**The United Laboratories International Holdings Limited**  
**Tsoi Hoi Shan**  
*Chairman*

Hong Kong, 4 August 2023

*As at the date of this announcement, the Board comprises Mr. Tsoi Hoi Shan, Mr. Leung Wing Hon, Ms. Choy Siu Chit, Mr. Fang Yu Ping, Ms. Zou Xian Hong and Ms. Zhu Su Yan as executive directors; and Mr. Chong Peng Oon, Prof. Song Ming and Dr. Fu Qiushi as independent non-executive directors.*